Disease | refractory anemia |
Phenotype | C0026986|myelodysplastic syndrome |
Sentences | 11 |
PubMedID- 25428262 | The splicing factor sf3b1 is the most commonly mutated gene in the myelodysplastic syndrome (mds), particularly in patients with refractory anemia with ring sideroblasts (rars). |
PubMedID- 21226301 | An 85-year-old woman, who had been given a diagnosis of myelodysplastic syndrome with refractory anemia 2 years previously and required blood transfusion once a month, was admitted with complaints of fever, general fatigue, and dry cough. |
PubMedID- 24716056 | Final diagnosis was high-grade myelodysplastic syndrome consistent with refractory anemia with excess blasts. |
PubMedID- 20569983 | We performed an open-labeled single-arm prospective phase ii clinical trial of vitamin k(2) (menatetrenone: vk2) monotherapy and vk2 plus 1alpha-hydroxyvitamin d(3) (alfacalcidol: vd3) combination therapy for myelodysplastic syndromes (mds) with refractory anemia and refractory cytopenia with multilineage dysplasia, having either low or intermediate-1 risks of the ipss. |
PubMedID- 24958999 | The goal of this study was to explore the plasma proteome of myelodysplastic syndrome (mds) patients with refractory anemia with excess blasts subtype 2 (raeb-2) in comparison to healthy controls. |
PubMedID- 23897263 | Correlation between dysplastic lineage and type of cytopenia in myelodysplastic syndromes patients with refractory anemia according to the fab classification. |
PubMedID- 20052416 | When we examined chk1 expression in this data set, we found it significantly decreased in patients suffering from myelodysplastic syndromes with refractory anemia with blasts [29] (figure 7b). |
PubMedID- 26171179 | The aim of this the study was to verify that biosimilar epoetin-alpha is similar in terms of efficacy, safety and cost to originator epoetin-alpha for the treatment of refractory anemia in patients with myelodysplastic syndrome. |
PubMedID- 26493409 | Since the patient refused bone marrow evaluation, she was initially treated with erythropoietin therapy based on the assumption that she may have an underlying refractory anemia associated with myelodysplastic syndrome or anemia of chronic disease. |
PubMedID- 21434945 | In many patients with refractory anemia associated with lower risk myelodysplastic syndromes and a 5q chromosome deletion, lenalidomide leads to transfusion independence, considerably improving quality of life. |
PubMedID- 20037898 | The findings were diagnostic of myelodysplastic syndrome with refractory anemia with excess of blasts in accordance with the world health organization criteria modified for pediatric age group. |
Page: 1